At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Tislelizumabdrug
Likely dose
Tislelizumab 200 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Early-Stage (Stage II-III) Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating Tislelizumab for Colorectal Cancer. Completed, enrolled 33 participants across 8 sites.
Detailed Summary
The main purpose of this study was to help meet the medical needs of people in China with certain types of solid tumors that have specific genetic changes called microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). The study looked at how well the drug tislelizumab works and how safe it is when given before surgery (neoadjuvant treatment) for these types of tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartJan 2022
Primary CompletionSep 2023
Study CompletionJan 2025
TodayJul 2026
First PostedNov 10, 2021
Enrollment StartJan 26, 2022
Primary CompletionSep 26, 2023
Study CompletionJan 3, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.6 years ago
Interventions
Tislelizumabdrug
200 milligrams (mg) administered through an intravenous (IV) infusion once every 3 weeks for 3 treatment cycles